0.29
+0.0194(+7.10%)
Currency In USD
| Previous Close | 0.27 |
| Open | 0.28 |
| Day High | 0.29 |
| Day Low | 0.26 |
| 52-Week High | 1.48 |
| 52-Week Low | 0.2 |
| Volume | 623,537 |
| Average Volume | 1.89M |
| Market Cap | 75.42M |
| PE | -0.97 |
| EPS | -0.3 |
| Moving Average 50 Days | 0.27 |
| Moving Average 200 Days | 0.63 |
| Change | 0.02 |
If you invested $1000 in Adaptimmune Therapeutics plc (ADAP) 10 years ago, it would be worth $19.74 as of June 01, 2025 at a share price of $0.293. Whereas If you bought $1000 worth of Adaptimmune Therapeutics plc (ADAP) shares 5 years ago, it would be worth $25.13 as of June 01, 2025 at a share price of $0.293.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025
Newsfile
May 07, 2025 4:00 PM GMT
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provid
Adaptimmune Provides Q4 and Full Year 2024 Business Update
Newsfile
Mar 20, 2025 11:00 AM GMT
TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achievedLete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026Corporate r
Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
Newsfile
Mar 12, 2025 8:54 PM GMT
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and pro